[HTML][HTML] Cost-effectiveness of pharmacogenomics-guided prescribing to prevent gene-drug-related deaths: A decision-analytic model
CH van der Wouden, H Marck, HJ Guchelaar… - Frontiers in …, 2022 - frontiersin.org
Aim: Prospective studies support the clinical impact of pharmacogenomics (PGx)-guided
prescribing to reduce severe and potentially fatal adverse effects. Drug-gene interactions …
prescribing to reduce severe and potentially fatal adverse effects. Drug-gene interactions …
[HTML][HTML] Simulating clinical trials for model-informed precision dosing: using warfarin treatment as a use case
Treatment response variability across patients is a common phenomenon in clinical practice.
For many drugs this inter-individual variability does not require much (if any) …
For many drugs this inter-individual variability does not require much (if any) …
[HTML][HTML] Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing …
CH van der Wouden, S Böhringer… - Pharmacogenetics …, 2020 - journals.lww.com
Objectives Pharmacogenetic panel-based testing represents a new model for precision
medicine. A sufficiently powered prospective study assessing the (cost-) effectiveness of a …
medicine. A sufficiently powered prospective study assessing the (cost-) effectiveness of a …
[HTML][HTML] Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research
Comparative effectiveness research (CER) in genomic medicine (GM) measures the clinical
utility of using genomic information to guide clinical care in comparison to appropriate …
utility of using genomic information to guide clinical care in comparison to appropriate …
Personalized medicine: Genetic risk prediction of drug response
G Zhang, DW Nebert - Pharmacology & therapeutics, 2017 - Elsevier
Pharmacogenomics (PGx), a substantial component of “personalized medicine”, seeks to
understand each individual's genetic composition to optimize drug therapy––maximizing …
understand each individual's genetic composition to optimize drug therapy––maximizing …
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics
AL Beitelshees, D Voora, JP Lewis - … and personalized medicine, 2015 - Taylor & Francis
In recent years, substantial effort has been made to better understand the influence of
genetic factors on the efficacy and safety of numerous medications. These investigations …
genetic factors on the efficacy and safety of numerous medications. These investigations …
[HTML][HTML] The relationship among intestinal bacteria, vitamin K and response of vitamin K antagonist: a review of evidence and potential mechanism
H Yan, Y Chen, H Zhu, WH Huang, XH Cai, D Li… - Frontiers in …, 2022 - frontiersin.org
The vitamin K antagonist is a commonly prescribed effective oral anticoagulant with a
narrow therapeutic range, and the dose requirements for different patients varied greatly. In …
narrow therapeutic range, and the dose requirements for different patients varied greatly. In …
Ubiquitous pharmacogenomics (U-PGx): the time for implementation is now. An Horizon2020 program to drive pharmacogenomics into clinical practice
E Cecchin, R Roncato, HJ Guchelaar… - Current …, 2017 - ingentaconnect.com
Although the clinical validity of a number of pharmacogenetic markers is nowadays a matter
of fact, and led authoritative scientific consortia as the Dutch Pharmacogenetic Working …
of fact, and led authoritative scientific consortia as the Dutch Pharmacogenetic Working …
The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective 'real-world'inception cohort study
V Roldán, S Cancio, J Gálvez, M Valdés… - The American journal of …, 2015 - Elsevier
Objectives International guidelines recommend that an average individual time in
therapeutic range should be> 65% to 70% for optimal efficacy and safety outcomes while …
therapeutic range should be> 65% to 70% for optimal efficacy and safety outcomes while …
[HTML][HTML] Warfarin therapy and VKORC1 and CYP genotype
L Dean - 2018 - europepmc.org
Warfarin (brand name Coumadin) is an anticoagulant (blood thinner). Warfarin acts by
inhibiting the synthesis of vitamin K-dependent clotting factors and is used in the prevention …
inhibiting the synthesis of vitamin K-dependent clotting factors and is used in the prevention …